Literature DB >> 16512619

[Proinflammatory cytokines in children with idiopathic headache].

Aleksandra Gergont1, Marek Kaciński, Przemko Kwinta.   

Abstract

OBJECTIVES: The pathogenesis of primary headaches is differential, with a neurogenic inflammation participation. THE AIM: The aim of this research was to establish whether inflammation participates in the pathogenesis of migraine and tension-type headaches (ETTH). In order to establish this, the levels of interleukin-6 (IL-6), interleukin-1 beta (IL-1beta), tumor necrosis factor (TNF) and soluble TNF receptor type I (sTNFRI) were detected in groups with headaches during headache-free interval and in controls and in the blood of children with idiopathic headaches to detect changes during headache attack.
MATERIAL AND METHODS: 30 children with migraine were included (16 with aura and 14 without aura), 17 boys and 13 girls aged 10-17 years (mean 13.5). The group with ETTH consisted of 31 patients, 24 girls and 7 boys, aged 6-17 years (mean 13.5). The control group, 28 children without headache, diagnosed with non-inflammatory orthopedic diseases, consisted of 15 boys and 13 girls, aged 7-17 years (mean 13.0). When the pain started during hospitalization, the blood was sampled in the first hour of the headache, then 3 hours and 6 hours since headache started (if headache persisted), and 6 hours after its termination. Two days after the pain termination, the blood samples were collected in children suffering from headaches, as the headache-free measurements and in controls under the same conditions at 7 a.m. after awakening. The cytokine level was established using Biosource kits, all 326 samples were processed. The statistical assessment was conducted.
RESULTS: No differences were detected in cytokine levels between the groups with migraine and ETTH and with comparison to controls during headache-free interval and during headache attack as well. However, it was established that in 12/30 children with migraine there was a significant increase in IL-6 level in the first hour of the migraine attack. This group consisted of 12 children with TNF level higher and the tendency toward decrease in sTNFRI was established, 3 hours since headache started, as compared to 18/30 children with migraine but without increase in IL-6. The correlation between the level of cytokines and age and weight was not detected. Also no correlation was established between cytokine levels and leukocyte and thrombocyte count.
CONCLUSION: 1. Changes of the level of IL-6, IL-1beta, TNF and sTNFRI in the blood of children with idiopathic headache do not indicate a significant role of inflammatory process in its pathogenesis. 2. Although the significant increase in IL-6 levels observed in several children in the first hour of the migraine attack may suggest that neurogenic inflammation participates in the pathogenesis of migraine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16512619

Source DB:  PubMed          Journal:  Przegl Lek        ISSN: 0033-2240


  4 in total

1.  Recurrent headaches may be caused by cerebral toxoplasmosis.

Authors:  Joseph Prandota; Anna Gryglas; Aleksander Fuglewicz; Agata Zesławska-Faleńczyk; Barbara Ujma-Czapska; Leszek Szenborn; Janusz Mierzwa
Journal:  World J Clin Pediatr       Date:  2014-08-08

2.  Polymorphism in apolipoprotein E among migraineurs and tension-type headache subjects.

Authors:  Ravi Gupta; Vivek Kumar; Kalpana Luthra; Basudeb Banerjee; Manjeet Singh Bhatia
Journal:  J Headache Pain       Date:  2009-01-31       Impact factor: 7.277

3.  Comparison of oxidative stress among migraineurs, tension-type headache subjects, and a control group.

Authors:  Ravi Gupta; Rahul Pathak; Manjeet Singh Bhatia; Basu Deb Banerjee
Journal:  Ann Indian Acad Neurol       Date:  2009-07       Impact factor: 1.383

4.  The Prevalence of Headache in Crohn's Disease: Single-Center Experience.

Authors:  Ulker Anadol Kelleci; Turan Calhan; Abdurrahman Sahin; Resul Kahraman; Kamil Ozdil; Haci Mehmet Sokmen; Destina Yalcin
Journal:  Gastroenterol Res Pract       Date:  2016-01-19       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.